Javascript must be enabled to continue!
The Binding of EGFR to GM1(3) Hosted in Lipid Raft-Like Biomembranes Insighted by Plasmonic Resonance Techniques
View through CrossRef
We exploit Au/SiO2plasmonic structures to check the effective binding activity of GM1(3) gangliosides hosted in physiological-like biomembranes, in presence of the Epidermal Growth Factor Receptor (EGFR). To this aim, we used bilayers that support the propagation of optical surface plasmon modes (plasmonic transducers, PTs) or guided modes (Plasmon Waveguide Resonators, PWRs). First, we measured the binding of EGFR to GM1(3) by using PTs. Indeed, effective interactions were evidenced, but with faint signals that prevented resolving dissociation kinetics. In order to enhance the optical responses, we turned our attention to PWRs. We first refined the design of a previously adopted Au/SiO2PWR, finding that the nominal sensitivity is independent on SiO2thickness but strongly dependent on its residual losses, due typically to a nonoptimal deposition process. We fabricated an improved Au/SiO2resonator and tested the predicted signal enhancement by monitoring the binding of EGFR to GM3-enriched biomembranes. The measured signal was ~12-fold higher than that one measured using a PT, close to the maximum theoretical enhancement. The higher PWR response enabled us to detect the dissociation of EGFR from GM3, and the value of the apparent dissociation constant of the GM3-EGFR complex could be obtained.
Title: The Binding of EGFR to GM1(3) Hosted in Lipid Raft-Like Biomembranes Insighted by Plasmonic Resonance Techniques
Description:
We exploit Au/SiO2plasmonic structures to check the effective binding activity of GM1(3) gangliosides hosted in physiological-like biomembranes, in presence of the Epidermal Growth Factor Receptor (EGFR).
To this aim, we used bilayers that support the propagation of optical surface plasmon modes (plasmonic transducers, PTs) or guided modes (Plasmon Waveguide Resonators, PWRs).
First, we measured the binding of EGFR to GM1(3) by using PTs.
Indeed, effective interactions were evidenced, but with faint signals that prevented resolving dissociation kinetics.
In order to enhance the optical responses, we turned our attention to PWRs.
We first refined the design of a previously adopted Au/SiO2PWR, finding that the nominal sensitivity is independent on SiO2thickness but strongly dependent on its residual losses, due typically to a nonoptimal deposition process.
We fabricated an improved Au/SiO2resonator and tested the predicted signal enhancement by monitoring the binding of EGFR to GM3-enriched biomembranes.
The measured signal was ~12-fold higher than that one measured using a PT, close to the maximum theoretical enhancement.
The higher PWR response enabled us to detect the dissociation of EGFR from GM3, and the value of the apparent dissociation constant of the GM3-EGFR complex could be obtained.
Related Results
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract
EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four EGFR...
Effects of cyclodextrins on GM1-gangliosides in fibroblasts from GM1-gangliosidosis patients
Effects of cyclodextrins on GM1-gangliosides in fibroblasts from GM1-gangliosidosis patients
Abstract
Objectives
GM1-gangliosidosis is an inherited disorder characterized by the accumulation of GM1-gangliosides in many ti...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Effect of ground subsidence on piled raft foundation
Effect of ground subsidence on piled raft foundation
Extensive researches for piled rafts have been performed but the evaluation of their behavior in ground subsidence condition is still a challenge. In this study, centrifugal tests ...
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract B120: Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Abstract
Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to first generation rev...
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers which the leading cause of cancer-related death worldwide. Recently, epide...
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
It is indisputable that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) prolong progression-free survival in non-small-cell lung cancer (NSCLC) patients ...
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract
Introduction The first or second generation EGFR TKI drugs showed good overall response and progression free survival rates in EGFR mutation positive patien...

